Publications by authors named "Amy Delozier"

Claim this Profile
T
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.
Robert Bissonnette, Ronald Vender, Andreas Pinter, Leanne M Stanley, Carrie R Houts, Amy M DeLozier

J Dermatolog Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.
Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu-Huei Huang, Charles W Lynde, Amy M DeLozier

NEJM Evid· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis.
Laura K Ferris, Jerry Bagel, Yu-Huei Huang, Andrew E Pink, Stephen K Tyring, Amy M DeLozier

J Am Acad Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Eric L Simpson, Robert Bissonnette, Amy S Paller, Brett King, Jonathan I Silverberg, Amy M DeLozier

Br J Dermatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Thomas Bieber, Kristian Reich, Carle Paul, Yuichiro Tsunemi, Matthias Augustin, Amy M DeLozier

Br J Dermatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
David Rosmarin, Scott Fretzin, Lindsay Strowd, Marta Casillas, Amy M DeLozier

J Cutan Med Surg· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
Peter A Lio, Eric L Simpson, George Han, Jennifer Soung, Susan Ball, Amy M DeLozier

J Dermatolog Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
Brett King, Manabu Ohyama, Ohsang Kwon, Abraham Zlotogorski, Justin Ko, Amy M DeLozier

N Engl J Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata.
Heather L Gelhorn, Katelyn Cutts, Emily Edson-Heredia, Peter Wright, Amy Delozier

Dermatol Ther (Heidelb)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
Koji Masuda, Amy M Delozier, Jill Kolodsick, Andrew Buchanan, Andrew E Pink

Eur J Dermatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.
Brett A King, Natasha Atanaskova Mesinkovska, Brittany Craiglow, Chesahna Kindred, Justin Ko, Amy M DeLozier

J Am Acad Dermatol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort.
Yuki M F Andersen, Lea Nymand, Amy M DeLozier, Russel Burge, Emily Edson-Heredia

BMJ Open· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis.
Elizabeth Bacci, Anne Rentz, Julia Correll, Evangeline Pierce, Amy DeLozier

J Drugs Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
Jacob P Thyssen, Timo Buhl, Pablo Fernández-Peñas, Kenji Kabashima, Sherry Chen, Amy M DeLozier

Dermatol Ther (Heidelb)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Jonathan I Silverberg, Amy DeLozier, Luna Sun, Jacob P Thyssen, Brian Kim

Health Qual Life Outcomes· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Eric L Simpson, Seth Forman, Jonathan I Silverberg, Matthew Zirwas, Emanual Maverakis, Amy M DeLozier

J Am Acad Dermatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Jonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, Robert Bissonnette, Kenji Kabashima, Amy M DeLozier

JAMA Dermatol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
Clifton O Bingham, Susan J Bartlett, Carol Kannowski, Luna Sun, Amy M DeLozier

Arthritis Care Res (Hoboken)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Kristian Reich, Kenji Kabashima, Ketty Peris, Jonathan I Silverberg, Lawrence F Eichenfield, Amy M DeLozier

JAMA Dermatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of adult atopic dermatitis patients according to disease characteristics and demographics.
Jacob P Thyssen, Yuki M F Andersen, Ida Vittrup, Evangeline Pierce, Amy DeLozier

Dermatol Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Relevance of Skin Pain in Atopic Dermatitis.
Sonja Ständer, Eric L Simpson, Emma Guttman-Yassky, Jacob P Thyssen, Kenji Kabashima, Amy M DeLozier

J Drugs Dermatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study.
Peter A Lio, Andreas Wollenberg, Jacob P Thyssen, Evangeline J Pierce, Maria Jose Rueda, Amy M DeLozier

J Drugs Dermatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Emma Guttman-Yassky, Brett King, Amy M DeLozier

J Am Acad Dermatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.
Christine Radawski, Mark C Genovese, Brett Hauber, W Benjamin Nowell, Kelly Hollis, Amy M DeLozier

Rheumatol Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis.
Louise Newton, Amy M DeLozier, Philip C Griffiths, Jennifer N Hill, Stacie Hudgens

J Patient Rep Outcomes· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis